Cobo Marc received 9,038 BridgeBio Oncology Therapeutics shares and 43,700 derivative securities, while forfeiting 203 shares at $5.52 each on September 10, 2026. The transaction record separates common-stock awards, a share forfeiture and derivative securities, allowing investors to assess Cobo Marc’s resulting holdings across each instrument type.

Key Highlights

  • Cobo Marc’s 9,038-share award left the principal accounting officer with 14,344 shares.
  • A separate award added 43,700 derivative securities to Cobo Marc’s holdings.
  • The 203-share forfeiture represented about 1.4% of Cobo Marc’s prior share holding.

The filing reported an award of shares, a share forfeiture, and an award of derivative securities.

BridgeBio Awards Add Shares and Derivative Securities

After that award, Cobo Marc held 14,344 shares. The transaction carried code A. A separate code A transaction awarded Cobo Marc 43,700 derivative securities. The 203-share transaction carried code F.

Post-Transaction Holdings

The 9,038-share award represented about 63.0% of Cobo Marc’s resulting share holding. The 203-share forfeiture represented about 1.4% of the prior share holding, leaving Cobo Marc with 14,141 shares after the transaction. The derivative securities award represented about 100.0% of Cobo Marc’s resulting derivative securities holding. The filing reports these percentages for the respective share and derivative-security holdings.